Despite vaccines and treatments, SARS-CoV-2-the virus that causes COVID-19-continues to pose a global health threat, driven by new variants and its ability to hijack human cells in ways that still ...
The global pandemic may be over, but SARS-CoV-2 continues to infect people around the world. Indeed, the United States has recorded roughly 750 deaths from COVID-19 over the past month. Now, an siRNA ...
A study led by the University of Barcelona and the Spanish National Research Council's Institute for Advanced Chemistry of Catalonia (IQAC - CSIC) presents a new therapeutic tool capable of inhibiting ...
Researchers from the Institute for Basic Science of Korea and collaborating institutions have designed a new class of peptide-based inhibitors targeting a crucial interface within the SARS-CoV-2 ...
Theodora Hatziioannou used her expertise on HIV-1 to gain insights into SARS-Co-V-2, and vice versa. The potential ...
Interna Therapeutics, a clinical-stage biopharmaceutical company announced today that it has signed an agreement with the University of Oxford to conduct a Phase IIa human challenge trial evaluating ...
ATLANTA — Starting antiviral treatment as late as 14 days after infection with SARS-CoV-2 may still be beneficial in hosts with compromised immune systems, who are at greatest risk of developing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results